The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
 
Sarina Anne Piha-Paul
Honoraria - Genentech
Research Funding - Abbvie; Cerulean Pharma; Curis; GlaxoSmithKline; Helix BioPharma; Incyte; Medivation; Merck Sharp & Dohme; Novartis; Principa Biopharma; Puma Biotechnology; Roche; XuanZhu
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - ARIAD; Array BioPharma; Blend Therapeutics; Exelixis; Foundation Medicine; Foundation Medicine; Guardant Health; Guardant Health; Novartis; Novartis; Novartis; Novartis; Novartis; US Oncology
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase. U.S. Patent No. 8,901,120. Washington, D.C.:U.S. Patent and Trademark Office.
 
Chengkon Shih
Employment - XuanZhu
 
Bert H. O'Neil
Consulting or Advisory Role - Amgen; Bayer; Genentech/Roche; Lilly/ImClone
Travel, Accommodations, Expenses - Merck KGaA
 
Qinghong Zhou
Employment - Sihuan Pharmaceutical Holdings Group
 
Yuli Ding
Employment - Sihuan Pharmaceutical Holdings Group
 
Na Ou
Employment - XuanZhu
 
Tingting Yu
Employment - Sihuan Pharmaceutical Holdings Group